GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (XPAR:TNG) » Definitions » Institutional Ownership

Transgene (XPAR:TNG) Institutional Ownership : 1.20% (As of Jun. 05, 2024)


View and export this data going back to 1998. Start your Free Trial

What is Transgene Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Transgene's institutional ownership is 1.20%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Transgene's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Transgene's Float Percentage Of Total Shares Outstanding is 0.00%.


Transgene Institutional Ownership Historical Data

The historical data trend for Transgene's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transgene Institutional Ownership Chart

Transgene Historical Data

The historical data trend for Transgene can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 1.18 1.12 1.12 1.12 1.12 1.16 1.20 1.20 1.20 1.20

Transgene Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Transgene (XPAR:TNG) Business Description

Traded in Other Exchanges
Address
400 Boulevard Gonthier d’Andernach, Parc d’Innovation - CS80166, Illkirch-Graffenstaden, FRA, 67400
Transgene SA is a biotechnology company. It is involved in the business of discovering and focusing immune-targeted therapies for the treatment of cancer and infectious diseases. The company's clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. It is engaged in clinical research and development of therapeutic vaccines and immunotherapeutic products.

Transgene (XPAR:TNG) Headlines

No Headlines